摘要 |
Cyclopenta[g]quinazolines of the formula (I):-wherein: A is a group OR or NR<SUP>0</SUP>R<SUP>1 </SUP>wherein R<SUP>0 </SUP>and R<SUP>1 </SUP>are each independently hydrogen C<SUB>1-4 </SUB>alkyl, C<SUB>3-4 </SUB>alkenyl, C<SUB>3-4 </SUB>alkynyl, C<SUB>2-4 </SUB>hydroxyalkyl, C<SUB>2-4 </SUB>halogenoalkyl or C<SUB>1-4 </SUB>cyanoalkyl, or R<SUP>0 </SUP>and R<SUP>1 </SUP>together with the intermediate N form a five- or six-membered heterocyclic ring, p is an integer in the range 1 to 4, R<SUP>2 </SUP>is hydrogen, C<SUB>1-4 </SUB>alkyl, C<SUB>3-4 </SUB>alkenyl, C<SUB>3-4 </SUB>alkynyl, C<SUB>2-4 </SUB>hydroxyalkyl, C<SUB>2-4 </SUB>halogenoalkyl or C<SUB>1-4 </SUB>cyanoalkyl; Ar<SUP>1 </SUP>is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C<SUB>1-4 </SUB>alkyl and C<SUB>1-4 </SUB>alkoxy, and R<SUP>3 </SUP>is a group of one of the following formulae: -A<SUP>1</SUP>-Ar<SUP>2</SUP>-A<SUP>2</SUP>-Y<SUP>1</SUP>-A<SUP>5</SUP>-CON(R)CH(Y<SUP>4</SUP>)Y<SUP>5</SUP>-A<SUP>8</SUP>-X-Ar<SUP>4 </SUP>and pharmaceutically acceptable salts or esters thereof are of therapeutic value particularly in the treatment of cancer
|